Login to Your Account

Amgen Revenues Up; Stock Drops Down On Data Delay

By Karen Pihl-Carey

Friday, January 27, 2006
While Amgen Inc. recorded an 18 percent increase in revenues for 2005, the company's stock slid Thursday when it failed to release much-anticipated data for its colorectal cancer drug panitumumab. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription